secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0000950170-25-014153
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio reports 3 patients each enrolled in Phase 1 trials of ADI-001 LN and ADI-270 ccRCC
--------------------------------------------------------------------------------

- ADI-001 LN Phase 1: 3 patients enrolled as of Feb 2025; first dosed Nov 2024; ~12 sites activated; preliminary data due H1 2025.
- ADI-001 additional autoimmune indications: Phase 1 enrollment to start Q1 2025 for SLE, systemic sclerosis, IIM, stiff person syndrome; preliminary data H2 2025.
- ADI-270 ccRCC Phase 1: 3 patients enrolled; first dosed Dec 2024; ~7 sites activated; preliminary data expected H1 2025.
- ANCA-associated vasculitis enrollment planned for H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025014153/0000950170-25-014153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025014153/acet-20250205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-014153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer